Table 3.
Baseline and one-year follow-up imaging and functional parameters inpatients who completed treatment with diflunisal.
| VARIABLE | Visit 0 | Visit 1 | p |
|---|---|---|---|
| Transthoracic Echocardiogram | |||
| TAPSE (mm, IQR) (n = 16) | 16.5 (15.3–21.0) | 18.0 (13.5–27.5) | 0.285 |
| LVEF Simpson biplane (%, ± SD) (n = 16) | 49.8 ± 11.0 | 51.9 ± 9.6 | 0.303 |
| E/E’ (n = 16) | 16.2 ± 4.6 | 16.3 ± 4.7 | 0.947 |
| Vein cava diameters (mm) (n = 16) | 16.0 (15.0–18.0) | 15.5 (14.3–17.0) | 0.752 |
| GLS LV (%, ± SD) (n = 9) | −11.2 ± 3.9 | −10.6 ± 5.3 | 0.728 |
| GLS RV (%, ± SD) (n = 9) | −10.3 ± 4.5 | −9.7 ± 3.5 | 0.523 |
| GLS LA (%, ± SD) (n = 9) | 9.1 ± 5.6 | 6.4 ± 6.8 | 0.181 |
| Cardiac Magnetic Resonance | |||
| LVEF (%, ± SD) (n = 9) | 56 ± 7.2 | 59 ± 8.3 | 0.376 |
| LVMi (g/m2, ± SD) (n = 9) | 53.2 ± 32.3 | 71.3 ± 36.0 | 0.139 |
| Native T1 (ms, ± SD) (n = 9) | 1424.9 ± 51.9 | 1446.9 ± 54.8 | 0.004 |
| Post-contrast T1 (ms, ± SD) (n = 9) | 524.8 ± 68.1 | 499.7 ± 52.9 | 0.130 |
| ECV (%, ± SD) (n = 9) | 40.7 ± 8.3 | 42.7 ± 9.4 | 0.415 |
| T2 (ms, IQR) (n = 9) | 55.3 (52.7–58.7) | 58.8 (54.6–60.2) | 0.401 |
| 6-min Walk Test (6MWT) | |||
| Distance (m, ± SD) (n = 9) | 238.5 ± 66.7 | 223.8 ± 64.1 | 0.626 |
Quantitative data following a normal distribution are presented as mean ± standard deviation, those not normally distributed are displayed as median (interquartile range), and qualitative variables are presented as percentages. ECV = extracellular volume; GLS = global longitudinal strain; LA = left atrium; LVMi = left ventricular mass indexed; LV = left ventricle; LVEF = left ventricular ejection fraction; RV = right ventricle; TAPSE = tricuspid annular plane systolic excursion.